Corona Remedies has acquired Wokadine brand from Dr. Reddy’s Laboratories in India.

The acquisition, effective March 30, marks the company’s entry into the ₹648 crore Povidone Iodine market in India. Wokadine is ranked number two in the market and the brand holds strong potential for accelerated growth under its stewardship, Corona said on Monday.

Wokadine comprises 14 SKUs having different applications. The company said the acquisition will be fully funded through internal accruals and cash.

For Corona Remedies, which continuously assesses both organic and inorganic growth opportunities, the latest acquisition will enhance and strengthen existing product portfolio, V-P Corporate Strategy and Business Development Tejas Kothari said in a release.


Leave a Reply

Your email address will not be published. Required fields are marked *